Intelligence · Clinical Development
Pipeline search results
Programs matching “docetaxel” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 38 pipeline programs matching "docetaxel" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
2020HXFH037
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
5-Fu/epirubicin/CTX following Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
DOCETAXEL
Pfizer Australia Pty Ltd
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Datopotamab deruxtecan, DOCETAXEL
Daiichi Sankyo
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
Datopotamab deruxtecan, DOCETAXEL
AstraZeneca AB
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
1 trial -
Docetaxel
Sanofi Pasteur
Non-small Cell Lung Cancer
1 trial -
Docetaxel
AstraZeneca
Prostate Cancer
1 trial -
Docetaxel+lobaplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
1 trial -
Docetaxel, cisplatin and fluorouracil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Doxorubicine + docetaxel sequential
Sanofi Pasteur
Breast Neoplasms
1 trial -
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
1 trial -
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer
2 trials -
Paclitaxel or docetaxel + Cisplatin or carboplatin
The First People's Hospital of Lianyungang
Uterine Cervical Neoplasms
1 trial -
Telisotuzumab Vedotin, DOCETAXEL
AbbVie Deutschland GmbH & Co. KG
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer
1 trial -
placebo plus docetaxel
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
1 trial -
20170512
The First People's Hospital of Lianyungang
Triple-Negative Breast Cancer
1 trial -
Anlotinib combined Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
BNT327, DOCETAXEL
BioNTech SE
Non-small Cell Lung Cancer
1 trial -
CMUH-HO-NPC001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Head and Neck Carcinoma
1 trial -
Docetaxel
Hospital Authority, Hong Kong
Non Small Cell Lung Cancer
1 trial -
Docetaxel
Merck KGaA, Darmstadt, Germany
Castration-Resistant Prostatic Cancer
1 trial -
Docetaxel
Takeda
Non-small Cell Lung Cancer
1 trial -
Docetaxel
BRIGHT MINDS BIOSCIENCES INC.
Prostatic Neoplasms
1 trial -
Docetaxel
Karyopharm Therapeutics Inc
Recurrent Squamous Cell Lung Carcinoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.